Collectively, while these data provide support for ICOS stimulation and PD-1 blockade as a therapeutic strategy for cancer, they also underscore the need to continuously refine our understanding of the dynamic TME and the translational efforts that accompany drug development to identify disease indications and patients who could benefit from these novel therapies, and the need for randomized survival data to characterize their clinical benefit potential. Here, ICOS is linked to cancer.